Imagine you have heart failure. Your doctor prescribes a medication that could keep you out of the hospital. But when they ask your insurance to pay for it, the answer is no. The reason? The insurance company thinks the drug is only for diabetes.
This isn't a rare glitch. It’s a major barrier for patients in Jordan, and likely in many other places too.
A new study in Frontiers in Medicine uncovers why this happens. It shows that even when doctors know a drug works for heart failure, insurance systems can block it. This leaves patients without a key treatment they need.
Heart failure is a serious condition where the heart can't pump blood well. It affects millions of people worldwide. It can cause shortness of breath, fatigue, and swelling in the legs.
Doctors have a powerful tool to help: SGLT2 inhibitors. These drugs were first made for diabetes. But research now shows they are "cornerstone therapy" for heart failure. They work for patients with or without diabetes. They help people stay healthier and out of the hospital.
But getting this drug isn't easy.
In Jordan, doctors know about these benefits. They have good knowledge and a positive attitude toward the drug. Yet, they rarely prescribe it for heart failure. Why? Because the insurance approval process is a maze.
The Old Way vs. The New Way
For years, doctors saw SGLT2 inhibitors as diabetes drugs. That was their only approved use. This old view is still stuck in many insurance systems.
But here’s the twist: New guidelines say these drugs are for heart failure, too. Major heart organizations recommend them. The science is clear.
The study found a huge gap between this new evidence and old insurance rules. Insurance physicians—those who approve or deny coverage—often don’t see the new data. They stick to the old label: "diabetes only."
This creates a conflict. The treating doctor wants to follow the new guidelines. The insurance doctor follows the old rules. The patient is caught in the middle.
How the System Works (or Doesn’t)
Think of the insurance process like a locked door. The doctor has the key—the prescription. But the insurance company holds the master lock.
In this case, the lock is mislabeled. The insurance system thinks the key only fits a diabetes door. So it rejects the request for a heart failure patient.
The study found this misclassification is the biggest reason for denial. Insurance physicians who saw the drug as diabetes-only were 80% more likely to reject it.
Other factors made it worse. If the prescribing doctor wasn’t a heart specialist, approval was less likely. If there was no clear insurance guideline for heart failure, approval was rare.
The system is set up to protect costs. But in doing so, it blocks effective care.
Researchers surveyed 312 doctors in Jordan. Half were treating doctors (like family doctors or internists). The other half worked for insurance companies, deciding which drugs to approve.
They asked about their knowledge, attitudes, and prescribing habits. Then, they interviewed a smaller group to understand the "why" behind the numbers.
Treating doctors knew the drug worked for heart failure. About 70% had good knowledge. Most had a positive attitude. But only a small fraction actually prescribed it for heart failure.
The reason was clear: insurance denial.
Fewer than one in three insurance approvals for heart failure went through—unless the patient also had diabetes. If the patient only had heart failure, the approval rate dropped.
The biggest predictor of rejection? The insurance doctor’s belief that the drug is only for diabetes. This single belief overrode all the medical evidence.
Other barriers included:
- No clear insurance protocol for heart failure use.
- Non-cardiologist prescribers faced more scrutiny.
- Cost concerns and defensive decision-making by insurance doctors.
The data shows a system where evidence is ignored because of outdated labels.
Here’s the Catch
The study was done in Jordan. But this isn’t just a Jordan problem. Many countries face similar issues. Insurance systems are slow to update. They often lag years behind new medical research.
The researchers concluded that barriers are "predominantly systemic." This means the problem isn’t with the doctors or the drugs. It’s with the insurance framework.
They call for policy changes. Insurance companies need to update their rules. They need to align with current heart failure guidelines. Standard criteria for approval would help. So would involving doctors and patients in the process.
If you have heart failure, ask your doctor about SGLT2 inhibitors. They are a proven treatment. But be prepared for insurance hurdles.
This study doesn’t mean the drug is unavailable. It means the path to getting it might be bumpy. Talk to your doctor about how to appeal insurance denials. Patient advocacy can help.
This doesn’t mean this treatment is available yet. It means the system needs to catch up with the science.
This study was done in one country. Results might differ elsewhere. It relied on self-reported surveys, which can be biased. The sample size was moderate, not huge. And it focused on one point in time, not long-term trends.
What happens next? The study suggests policy interventions. Insurance companies need to update reimbursement structures. Standardized criteria for heart failure drugs are essential.
In Jordan, this means working with stakeholders—doctors, patients, insurers—to fix the system. Globally, it’s a reminder that new science must be matched by new policies.
Research takes time. But so do insurance changes. The goal is to make sure proven treatments reach the patients who need them.